Hamid Namazi. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Carpal Tunnel Syndrome/drug therapyCarpal Tunnel Syndrome/immunologyCarpal Tunnel Syndrome/physiopathologyGene Expression Regulation/drug effectsGene Expression Regulation/geneticsImmunosuppressive Agents/pharmacologyImmunosuppressive Agents/therapeutic useNF-kappa B/antagonists & inhibitorsNF-kappa B/metabolismNucleic Acid Synthesis Inhibitors/pharmacologyNucleic Acid Synthesis Inhibitors/therapeutic useOligopeptides/drug effectsOligopeptides/metabolismProtein-Serine-Threonine Kinases/drug effectsProtein-Serine-Threonine Kinases/metabolismReceptor, Transforming Growth Factor-beta Type IReceptors, Transforming Growth Factor beta/drug effectsReceptors, Transforming Growth Factor beta/metabolismRifampin/pharmacologyRifampin/therapeutic useSmad2 Protein/antagonists & inhibitorsSmad2 Protein/metabolismSmad3 Protein/antagonists & inhibitorsSmad3 Protein/metabolismTranscription Factor AP-1/antagonists & inhibitorsTranscription Factor AP-1/metabolismTransforming Growth Factor beta/antagonists & inhibitorsTransforming Growth Factor beta/immunology
Substances： See more » Immunosuppressive AgentsNF-kappa BNucleic Acid Synthesis InhibitorsOligopeptidesReceptors, Transforming Growth Factor betaSMAD2 protein, humanSMAD3 protein, humanSmad2 ProteinSmad3 ProteinTranscription Factor AP-1Transforming Growth Factor betaProtein-Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IgoralatideRifampin
Year: 2008 PMID： 18262848 DOI： 10.1016/j.jpain.2008.01.325
Source DB: PubMed Journal: J Pain ISSN： 1526-5900 Impact factor: 5.820